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Microcontainers as oral drug delivery systems for small molecules and proteins 
 
Purpose (words 101) 
In the present work, the potential of utilizing microcontainers as oral delivery systems 
for enhancing delivery of a small protein, insulin, and a poorly soluble drug, 
furosemide, is tested in vivo. The applied types of microcontainers comprise small 
reservoirs with a flat base and are prepared from polymers such as poly-L-lactic acid 
(PLLA) (Nagstrup 2011 DOI) and the epoxy SU-8 (Nielsen 2012 DOI). In previous 
studies, they have shown promising properties as drug delivery systems for oral 
administration (Ainslie et al. doi:10.1002/smll.200901254) due to their mucus 
adhesive properties of the flat base material and unidirectional drug release (Tao et al. 
doi:10.1016/S0168-3659(03)00005-1).  
 
Methods (words 119) 
SU-8 microcontainers were prepared (Nielsen et al. doi: 10.1016/j.ejpb.2012.03.017) 
and filled with insulin or amorphous furosemide sodium salt (AFSS) followed by 
coating the cavity of microcontainers with Eudragit-L100. Microcontainers were 
transferred to capsules (size 9) and dosed to rats (fed state) by oral gavage (n=6), 
dosing 40 IU/kg insulin or 15 mg/kg AFSS. As controls, dosing of Eudragit-L100 
coated capsules (2 %w/v) containing insulin or AFSS as well as subcutaneous 
administration of insulin (1.5 IU/kg) was used. Blood samples were collected during 6 
h for insulin and 24 h for AFSS. After administration of insulin, blood glucose was 
monitored simultaneously. The plasma insulin concentration was evaluated using an 
ELISA kit and furosemide was quantified by liquid chromatography–mass 
spectrometry. 
 
Results (words 49) 
For insulin, no significant effect was observed in the blood glucose and plasma 
insulin levels by using the microcontainers as oral delivery system when compared to 
empty microcontainers. When dosing AFSS in microcontainers, however, a 
furosemide bioavailability of 220±43% was observed relative  to dosing of Eudragit-
coated capsules containing AFSS. 
 
Conclusion (words 60) 
No significant effect was observed for insulin. Further formulation development is 
therefore essential, before the full potential of utilizing microcontainers for oral 
protein delivery can be explored. However, microcontainers show promising 
properties as oral drug delivery system for the poorly soluble drug furosemide, as the 
bioavailability of furosemide increased 2.2-fold after oral administration in 




Figure 1: Image of a drug-filled microcontainer 
 
Figure 2: Image of the microcontainer after drug loading and coating on the cavity of 
the microcontainer with Eudragit L100 
 
